Client Result

RNA-based Oncology Biomarker Market Landscape

Project Overview

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

DeciBio Approach

Secondary Research

  • Conducted de-novo analysis of rearrangements and GEP biomarkers, technologies, and indications from publications / abstracts 
  • Extracted rearrangement and GEP biomarker data from clinical trials and profiled commercial rearrangement / gene expression assays;
  • Tiered biomarkers into low, mid, and high priority based on overall presence and inclusion in guidelines, publications, and clinical trials

‍Primary Research

  • Conducted telephone interviews with oncologists, hematologists,  pathologists, laboratory directors, pharma experts, and technology KOLs to gather insights about current RNA biomarker use, vendor perceptions, selection criteria, and future trends
  • Interviews were split evenly between rearrangement and GEP focus and represented community hospitals, academic medical centers, pharma, and diagnostics

‍

At a glance
30
Stakeholder Interviews
>580
Clinical Trials Analyzed
>60
Commercial Rearrangement / GEP Assays Profiled
Outcomes

DeciBio delivered an in-person presentation to a client team, with the results of the analysis synthesized for understanding current patterns and future trends in RNA-based oncology biomarkers

DeciBio delivered Excel databases of findings and analyses of: 

  • Rearrangement / GEP biomarker data from clinical trials
  • Rearrangement and GEP genes / signatures from commercial assays
  • Commercial rearrangement and GEP assay profiles, including technology, plex, interviewee satisfaction scores, and competitive differentiation

‍

Timeline

5 weeks

Geographic Scope

U.S.

Industry

Clinical Diagnostics

capabilities

Voice-Of-Customer Research

Competitive Analysis

Biomarker and Diagnostic Strategy

Customer Segmentation

Related Client Results
Clinical Diagnostics
Genetic Testing Lab Target Assessment
A large pharmaceutical company asked DeciBio to help it identify and evaluate clinical genetic testing labs for potential partnership or acquisition
Target Identification
Clinical Diagnostics
MRD Monitoring Market Assessment and Strategy
A diagnostics player wanted to determine which indications and use cases to target and develop a product road map for its planned MRD offering
Biomarker and Diagnostic Strategy
Go-to-Market Strategy
Clinical Diagnostics
Early Cancer Detection Competitor Landscape Monitoring
A top diagnostics player wanted to monitor the commercial, clinical, research, and corporate activities in the public domain for three of the key players in the cancer early detection market.
Competitive Analysis
Clinical Diagnostics
IVDR Diagnostics Strategy
A top-10 diagnostics company wanted to gauge laboratory preparedness and reactions to the impending implementation of IVDR, and how that would impact portfolio strategy
Voice-Of-Customer Research
Biomarker and Diagnostic Strategy

Precision Medicine is evolving at a rapid pace

Discover how we can help

Contact Us
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Precision Medicine. Precision Insights.
© DeciBio 2022. All rights reserved.
Privacy | Terms & Conditions